Morgan Stanley
NPCE icon

Morgan Stanley’s Neuropace NPCE Stock Holding History

Morgan Stanley’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.8M Buy
2,566,839
+19,055
+0.7% +$286K ﹤0.01% 2488
2025
Q4 		$39.3M Buy
2,547,784
+1,576
+0.1% +$21.1K ﹤0.01% 2319
2025
Q3 		$26.3M Sell
2,546,208
-38,865
-2% -$366K ﹤0.01% 2617
2025
Q2 		$28.8M Buy
2,585,073
+54,453
+2% +$681K ﹤0.01% 2451
2025
Q1 		$31.1M Buy
2,530,620
+38,790
+2% +$486K ﹤0.01% 2252
2024
Q4 		$27.9M Sell
2,491,830
-2,511
-0.1% -$21.8K ﹤0.01% 2418
2024
Q3 		$17.4M Buy
2,494,341
+23,199
+0.9% +$170K ﹤0.01% 2930
2024
Q2 		$18.7M Sell
2,471,142
-12,841
-0.5% -$130K ﹤0.01% 2740
2024
Q1 		$32.8M Sell
2,483,983
-2,437,449
-50% -$34.8M ﹤0.01% 2165
2023
Q4 		$50.7M Buy
4,921,432
+2,521,716
+105% +$20.1M ﹤0.01% 2435
2023
Q3 		$23.3M Buy
2,399,716
+40,850
+2% +$239K ﹤0.01% 2290
2023
Q2 		$10.6M Buy
2,358,866
+100,850
+4% +$456K ﹤0.01% 3100
2023
Q1 		$10.5M Buy
2,258,016
+69,423
+3% +$266K ﹤0.01% 3100
2022
Q4 		$3.26M Buy
2,188,593
+64,990
+3% +$144K ﹤0.01% 4120
2022
Q3 		$7.96M Buy
2,123,603
+138,414
+7% +$667K ﹤0.01% 3199
2022
Q2 		$9.83M Buy
1,985,189
+949,405
+92% +$6.27M ﹤0.01% 3080
2022
Q1 		$8.5M Buy
1,035,784
+769,556
+289% +$6.64M ﹤0.01% 3096
2021
Q4 		$2.68M Buy
266,228
+258,570
+3,376% +$3.36M ﹤0.01% 4337
2021
Q3 		$121K Buy
7,658
+66
+0.9% +$1.39K ﹤0.01% 6265
2021
Q2 		$181K Buy
+7,592
New +$176K ﹤0.01% 6066

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley's NPCE Position: Q1 2026 in Review

Morgan Stanley increased its Neuropace (NPCE) stake by 0.75% in Q1 2026, buying an estimated $286K and bringing the position to 2,566,839 shares worth $33.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2488.

Morgan Stanley first reported a position in NPCE in Q2 2021 and has held it in 20 quarters since. The position peaked at $50.7M in Q4 2023. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Morgan Stanley held 2,566,839 shares of Neuropace worth $33.8M as of Q1 2026.
  • Morgan Stanley bought 19,055 Neuropace shares in Q1 2026, an estimated $286K.
  • Neuropace made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2488 holding.
  • Morgan Stanley first reported a position in Neuropace in Q2 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Neuropace position peaked at $50.7M in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.